What was the primary endpoint of the Effasayil trial?

Featuring Brad Glick, DO, MPH | Board of Directors, American Academy of Dermatology (AAD); Program Director, Dermatology Residency, Larkin Health System, Palm Springs Campus; Assistant Clinical Professor of Dermatology, Herbert Wertheim College of Medicine, Miami, FL | Published September 01, 2023